ICLUSIG

Approval Id: 2e9cf318bec4a7c6
Drug Approval Canada Name: ICLUSIG
Product Name: ICLUSIG
Status: Marketed
Status Date: 2023-06-29
Original Market Date: 2015-08-21
Din: 02437333
Drug Class: Human
Dosage Form: Tablet
Route Of Administration: Oral
Schedule: Prescription
Ahfs: 10:00.00
Atc Original: L01EA05 PONATINIB
Atc Name: l 01 ea 05
Aig Number: 0156590001
Company Name: Takeda Pharmaceuticals U.S.A., Inc.
Company Address: 500 Kendall Street, Cambridge, Massachusetts, United States, 02142
Company Detail Path: /organization/takeda-pharmaceuticals-u-s-a-inc

PONATINIB (PONATINIB HYDROCHLORIDE)

15 MG

Authorized

Agency

Health Canada

Country

🇨🇦

Approval Date

Jul 4, 2025

Approval ID

2e9cf318bec4a7c6

Type

Standard